Capital Advisors Ltd. LLC Sells 114 Shares of Eli Lilly and Company (NYSE:LLY)

Capital Advisors Ltd. LLC lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 8.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,318 shares of the company’s stock after selling 114 shares during the quarter. Capital Advisors Ltd. LLC’s holdings in Eli Lilly and Company were worth $1,017,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of LLY. AMF Tjanstepension AB lifted its holdings in shares of Eli Lilly and Company by 113.7% in the 3rd quarter. AMF Tjanstepension AB now owns 331,786 shares of the company’s stock worth $293,964,000 after acquiring an additional 176,552 shares during the last quarter. Values Added Financial LLC lifted its holdings in shares of Eli Lilly and Company by 4.9% in the 3rd quarter. Values Added Financial LLC now owns 366 shares of the company’s stock worth $324,000 after acquiring an additional 17 shares during the last quarter. Heritage Oak Wealth Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 109.8% in the 3rd quarter. Heritage Oak Wealth Advisors LLC now owns 860 shares of the company’s stock worth $762,000 after acquiring an additional 450 shares during the last quarter. Hudock Inc. lifted its holdings in Eli Lilly and Company by 0.8% during the 3rd quarter. Hudock Inc. now owns 2,797 shares of the company’s stock valued at $2,478,000 after buying an additional 23 shares in the last quarter. Finally, Strategic Investment Solutions Inc. IL lifted its holdings in Eli Lilly and Company by 8.3% during the 3rd quarter. Strategic Investment Solutions Inc. IL now owns 676 shares of the company’s stock valued at $599,000 after buying an additional 52 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

LLY opened at $874.12 on Monday. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The firm has a fifty day moving average price of $801.33 and a 200 day moving average price of $847.66. Eli Lilly and Company has a 1 year low of $711.40 and a 1 year high of $972.53. The stock has a market cap of $828.82 billion, a P/E ratio of 74.65, a P/E/G ratio of 1.40 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company announced that its Board of Directors has initiated a share buyback plan on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to buy up to 2% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s management believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be issued a $1.50 dividend. The ex-dividend date is Friday, February 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.69%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s dividend payout ratio is currently 51.24%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on LLY shares. Citigroup decreased their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Berenberg Bank set a $970.00 price objective on shares of Eli Lilly and Company in a report on Thursday, January 16th. StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Finally, Wells Fargo & Company cut their target price on shares of Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Three investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,000.28.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.